Literature DB >> 33420492

Loss of the fragile X syndrome protein FMRP results in misregulation of nonsense-mediated mRNA decay.

Tatsuaki Kurosaki1,2, Naoto Imamachi3, Christoph Pröschel4,5, Shuhei Mitsutomi1,2,3, Rina Nagao1,2, Nobuyoshi Akimitsu3, Lynne E Maquat6,7.   

Abstract

Loss of the fragile X protein FMRP is a leading cause of intellectual disability and autism1,2, but the underlying mechanism remains poorly understood. We report that FMRP deficiency results in hyperactivated nonsense-mediated mRNA decay (NMD)3,4 in human SH-SY5Y neuroblastoma cells and fragile X syndrome (FXS) fibroblast-derived induced pluripotent stem cells (iPSCs). We examined the underlying mechanism and found that the key NMD factor UPF1 binds directly to FMRP, promoting FMRP binding to NMD targets. Our data indicate that FMRP acts as an NMD repressor. In the absence of FMRP, NMD targets are relieved from FMRP-mediated translational repression so that their half-lives are decreased and, for those NMD targets encoding NMD factors, increased translation produces abnormally high factor levels despite their hyperactivated NMD. Transcriptome-wide alterations caused by NMD hyperactivation have a role in the FXS phenotype. Consistent with this, small-molecule-mediated inhibition of hyperactivated NMD, which typifies iPSCs derived from patients with FXS, restores a number of neurodifferentiation markers, including those not deriving from NMD targets. Our mechanistic studies reveal that many molecular abnormalities in FMRP-deficient cells are attributable-either directly or indirectly-to misregulated NMD.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33420492     DOI: 10.1038/s41556-020-00618-1

Source DB:  PubMed          Journal:  Nat Cell Biol        ISSN: 1465-7392            Impact factor:   28.824


  64 in total

1.  Genetic variation in DPP6 is associated with susceptibility to amyotrophic lateral sclerosis.

Authors:  Michael A van Es; Paul W J van Vught; Hylke M Blauw; Lude Franke; Christiaan G J Saris; Ludo Van den Bosch; Sonja W de Jong; Vianney de Jong; Frank Baas; Ruben van't Slot; Robin Lemmens; Helenius J Schelhaas; Anna Birve; Kristel Sleegers; Christine Van Broeckhoven; Jennifer C Schymick; Bryan J Traynor; John H J Wokke; Cisca Wijmenga; Wim Robberecht; Peter M Andersen; Jan H Veldink; Roel A Ophoff; Leonard H van den Berg
Journal:  Nat Genet       Date:  2007-12-16       Impact factor: 38.330

2.  An alternative branch of the nonsense-mediated decay pathway.

Authors:  Wai-Kin Chan; Lulu Huang; Jayanthi P Gudikote; Yao-Fu Chang; J Saadi Imam; James A MacLean; Miles F Wilkinson
Journal:  EMBO J       Date:  2007-03-15       Impact factor: 11.598

Review 3.  Nonsense-mediated RNA decay in the brain: emerging modulator of neural development and disease.

Authors:  Samie R Jaffrey; Miles F Wilkinson
Journal:  Nat Rev Neurosci       Date:  2018-12       Impact factor: 34.870

4.  RNA homeostasis governed by cell type-specific and branched feedback loops acting on NMD.

Authors:  Lulu Huang; Chih-Hong Lou; Waikin Chan; Eleen Y Shum; Ada Shao; Erica Stone; Rachid Karam; Hye-Won Song; Miles F Wilkinson
Journal:  Mol Cell       Date:  2011-09-16       Impact factor: 17.970

Review 5.  Dysregulation and restoration of translational homeostasis in fragile X syndrome.

Authors:  Joel D Richter; Gary J Bassell; Eric Klann
Journal:  Nat Rev Neurosci       Date:  2015-09-09       Impact factor: 34.870

6.  A disease-associated mutation in the adhesion GPCR BAI2 (ADGRB2) increases receptor signaling activity.

Authors:  Ryan H Purcell; Camilo Toro; William A Gahl; Randy A Hall
Journal:  Hum Mutat       Date:  2017-09-20       Impact factor: 4.878

Review 7.  Fragile X syndrome.

Authors:  Randi J Hagerman; Elizabeth Berry-Kravis; Heather Cody Hazlett; Donald B Bailey; Herve Moine; R Frank Kooy; Flora Tassone; Ilse Gantois; Nahum Sonenberg; Jean Louis Mandel; Paul J Hagerman
Journal:  Nat Rev Dis Primers       Date:  2017-09-29       Impact factor: 52.329

Review 8.  Quality and quantity control of gene expression by nonsense-mediated mRNA decay.

Authors:  Tatsuaki Kurosaki; Maximilian W Popp; Lynne E Maquat
Journal:  Nat Rev Mol Cell Biol       Date:  2019-07       Impact factor: 94.444

9.  A post-translational regulatory switch on UPF1 controls targeted mRNA degradation.

Authors:  Tatsuaki Kurosaki; Wencheng Li; Mainul Hoque; Maximilian W-L Popp; Dmitri N Ermolenko; Bin Tian; Lynne E Maquat
Journal:  Genes Dev       Date:  2014-09-01       Impact factor: 11.361

10.  A GC-rich sequence feature in the 3' UTR directs UPF1-dependent mRNA decay in mammalian cells.

Authors:  Naoto Imamachi; Kazi Abdus Salam; Yutaka Suzuki; Nobuyoshi Akimitsu
Journal:  Genome Res       Date:  2016-12-09       Impact factor: 9.043

View more
  10 in total

1.  AKT constitutes a signal-promoted alternative exon-junction complex that regulates nonsense-mediated mRNA decay.

Authors:  Hana Cho; Elizabeth T Abshire; Maximilian W Popp; Christoph Pröschel; Joshua L Schwartz; Gene W Yeo; Lynne E Maquat
Journal:  Mol Cell       Date:  2022-06-07       Impact factor: 19.328

2.  Fmr1 exon 14 skipping in late embryonic development of the rat forebrain.

Authors:  Juliana C Corrêa-Velloso; Alessandra M Linardi; Talita Glaser; Fernando J Velloso; Maria P Rivas; Renata E P Leite; Lea T Grinberg; Henning Ulrich; Michael R Akins; Silvana Chiavegatto; Luciana A Haddad
Journal:  BMC Neurosci       Date:  2022-05-31       Impact factor: 3.264

Review 3.  Across Dimensions: Developing 2D and 3D Human iPSC-Based Models of Fragile X Syndrome.

Authors:  Azalea Lee; Jie Xu; Zhexing Wen; Peng Jin
Journal:  Cells       Date:  2022-05-24       Impact factor: 7.666

4.  NMD abnormalities during brain development in the Fmr1-knockout mouse model of fragile X syndrome.

Authors:  Tatsuaki Kurosaki; Hitomi Sakano; Christoph Pröschel; Jason Wheeler; Alexander Hewko; Lynne E Maquat
Journal:  Genome Biol       Date:  2021-11-16       Impact factor: 17.906

5.  Impaired Functional Connectivity Underlies Fragile X Syndrome.

Authors:  Lital Gildin; Rossana Rauti; Ofir Vardi; Liron Kuznitsov-Yanovsky; Ben M Maoz; Menahem Segal; Dalit Ben-Yosef
Journal:  Int J Mol Sci       Date:  2022-02-12       Impact factor: 5.923

6.  Sustained correction of hippocampal neurogenic and cognitive deficits after a brief treatment by Nutlin-3 in a mouse model of fragile X syndrome.

Authors:  Sahar Javadi; Yue Li; Jie Sheng; Lucy Zhao; Yao Fu; Daifeng Wang; Xinyu Zhao
Journal:  BMC Med       Date:  2022-05-13       Impact factor: 11.150

Review 7.  Human-Induced Pluripotent Stem Cell Technology: Toward the Future of Personalized Psychiatry.

Authors:  Alessandra Alciati; Angelo Reggiani; Daniela Caldirola; Giampaolo Perna
Journal:  J Pers Med       Date:  2022-08-20

8.  SF3B1 homeostasis is critical for survival and therapeutic response in T cell leukemia.

Authors:  Cuijuan Han; Alireza Khodadadi-Jamayran; Adam H Lorch; Qi Jin; Valentina Serafin; Ping Zhu; Yuliya Politanska; Limin Sun; Blanca T Gutierrez-Diaz; Marina V Pryzhkova; Hiam Abdala-Valencia; Elizabeth Thomas Bartom; Barbara Buldini; Giuseppe Basso; Sadanandan E Velu; Kavitha Sarma; Basil B Mattamana; Byoung-Kyu Cho; Rebecca C Obeng; Young Ah Goo; Philip W Jordan; Aristotelis Tsirigos; Yalu Zhou; Panagiotis Ntziachristos
Journal:  Sci Adv       Date:  2022-01-21       Impact factor: 14.957

9.  Fragile X Mental Retardation Protein and Cerebral Expression of Metabotropic Glutamate Receptor Subtype 5 in Men with Fragile X Syndrome: A Pilot Study.

Authors:  James Robert Brašić; Jack Alexander Goodman; Ayon Nandi; David S Russell; Danna Jennings; Olivier Barret; Samuel D Martin; Keith Slifer; Thomas Sedlak; Anil Kumar Mathur; John P Seibyl; Elizabeth M Berry-Kravis; Dean F Wong; Dejan B Budimirovic
Journal:  Brain Sci       Date:  2022-02-26

10.  Gene Variants Involved in Nonsense-Mediated mRNA Decay Suggest a Role in Autism Spectrum Disorder.

Authors:  Ana Rita Marques; João Xavier Santos; Hugo Martiniano; Joana Vilela; Célia Rasga; Luísa Romão; Astrid Moura Vicente
Journal:  Biomedicines       Date:  2022-03-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.